Kevin Liu
University of Auckland(NZ)Greenlane Clinical Centre(NZ)
Publications by Year
Research Areas
Herpesvirus Infections and Treatments, Multiple Myeloma Research and Treatments, Ocular Diseases and Behçet’s Syndrome, Acne and Rosacea Treatments and Effects, Peptidase Inhibition and Analysis
Most-Cited Works
- → Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial(2010)433 cited
- → Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials(2013)250 cited
- → Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study(2023)156 cited
- → Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study(2010)145 cited
- → Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye(2018)59 cited
- → Herpes Zoster Ophthalmicus Clinical Presentation and Risk Factors for Loss of Vision(2021)55 cited
- → Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial(2011)35 cited
- → Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma(2008)35 cited
- → Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)(2020)34 cited
- → Auckland Cataract Study IV: Practical application of NZCRS cataract risk stratification to reduce phacoemulsification complications(2019)21 cited